---
figid: PMC5883534__12918_2018_554_Fig4_HTML
figtitle: BRAF kinase inhibitor resistance and alternative activation of MAPK targets
  and pigmentation
organisms:
- Homo sapiens
- Bos taurus
- Trichomonas brixi
organisms_ner:
- Bos taurus
- Homo sapiens
- Danio rerio
pmcid: PMC5883534
filename: 12918_2018_554_Fig4_HTML.jpg
figlink: /pmc/articles/PMC5883534/figure/Fig4/
number: F4
caption: Pathway analysis of BRAF kinase                                 inhibitor
  resistance shows alternative activation of MAPK targets                                 and
  pigmentation. a Schematic representation of                                 regulatory
  network involving drug inhibition and non-genomic                                 selection
  for differential expression of driver genes that can                                 circumvent
  suppressed signaling. b Deregulation of MAPK                                 signaling
  with RNA-Seq data is mapped in red and blue for                                 differential
  upregulation and downregulation, respectively.                                     c
  Modulation of TGFB signaling leads to                                 downregulation
  of dual specific phosphatases, which are required to                                 switch
  MAPK signaling off. d Interconnectedness between                                 G-protein
  signaling and melanogenesis. Alternative activation of                                 melanoma
  pathways leads to increased eumelanin synthesis and                                 mitogenic
  survival. Photograph of cell pellets of melanoma cell                                 models
  and detected melanin. Left shows SK-MEL-28 melanoma cell                                 line,
  middle and right shows two different SK-MEL-28-BRAFi-resistant                                 melanoma
  cell lines with elevated melanin                             production
papertitle: Systems biology analysis of mitogen activated protein kinase                     inhibitor
  resistance in malignant melanoma.
reftext: Helma Zecena, et al. BMC Syst Biol. 2018;12:33.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.864619
figid_alias: PMC5883534__F4
figtype: Figure
redirect_from: /figures/PMC5883534__F4
ndex: 72792c06-deb2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5883534__12918_2018_554_Fig4_HTML.html
  '@type': Dataset
  description: Pathway analysis of BRAF kinase                                 inhibitor
    resistance shows alternative activation of MAPK targets                                 and
    pigmentation. a Schematic representation of                                 regulatory
    network involving drug inhibition and non-genomic                                 selection
    for differential expression of driver genes that can                                 circumvent
    suppressed signaling. b Deregulation of MAPK                                 signaling
    with RNA-Seq data is mapped in red and blue for                                 differential
    upregulation and downregulation, respectively.                                     c
    Modulation of TGFB signaling leads to                                 downregulation
    of dual specific phosphatases, which are required to                                 switch
    MAPK signaling off. d Interconnectedness between                                 G-protein
    signaling and melanogenesis. Alternative activation of                                 melanoma
    pathways leads to increased eumelanin synthesis and                                 mitogenic
    survival. Photograph of cell pellets of melanoma cell                                 models
    and detected melanin. Left shows SK-MEL-28 melanoma cell                                 line,
    middle and right shows two different SK-MEL-28-BRAFi-resistant                                 melanoma
    cell lines with elevated melanin                             production
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGF1
  - PDGFC
  - HGF
  - FGFR1
  - PDGFRA
  - EPHA2
  - BRAF
  - MAPK14
  - DUSP2
  - DUSP1
  - TF
  - EPAS1
  - TGFB3
  - ADCY1
  - EDNRB
  - GNAI2
  - SMAD2
  - YAP1
  - PRKACA
  - PLCB4
  - PRKCA
  - EP300
  - DCT
  - SMAD9
  - CREB3
  - MITF
  - OCA2
  - EFNA2
  - IL6
  - SOS1
  - KRAS
  - HRAS
  - NRAS
  - MAP3K1
  - MAP3K2
  - MAP3K3
  - MAP3K4
  - MAP3K5
  - MAP3K6
  - MAP3K7
  - MAP3K8
  - MAP3K9
  - MAP3K10
  - MAP3K11
  - MAP3K12
  - MAP3K13
  - MAP3K14
  - MAP3K15
  - MAP3K19
  - MAP3K20
  - MAP3K21
  - ARAF
  - RAF1
  - TAOK1
  - TAOK2
  - TAOK3
  - MAP2K3
  - MAP2K4
  - MAP2K5
  - MAP2K6
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - DUSP12
  - FOXG1
  - FOXH1
  - FOXM1
  - FOXQ1
  - FOXS1
  - FOXA1
  - FOXA2
  - FOXA3
  - FOXB1
  - FOXB2
  - FOXC1
  - FOXC2
  - FOXD1
  - FOXD2
  - FOXD3
  - FOXD4
  - FOXE1
  - FOXE3
  - FOXF1
  - FOXF2
  - FOXI1
  - FOXI2
  - FOXI3
  - FOXJ1
  - FOXJ2
  - FOXJ3
  - FOXK1
  - FOXK2
  - FOXL1
  - FOXL2
  - FOXN1
  - FOXN2
  - FOXN3
  - FOXN4
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - FOXP1
  - FOXP2
  - FOXP3
  - FOXP4
  - FOXR1
  - FOXR2
  - FOXD4L1
  - FOXD4L3
  - FOXD4L4
  - FOXD4L5
  - FOXD4L6
  - TGFBR1
  - TGFBR2
  - TGFBR3
  - GATAD1
  - CREB3L4
  - MAPK8
  - MAPK9
  - MAPK10
  - fgf1a
  - pdgfc
  - fgfr1a
  - pdgfra
  - epha2a
  - epha2b
  - rab1ab
  - braf
  - si:dkey-222f8.3
  - mapk14a
  - dusp2
  - dusp1
  - epas1b
  - tgfb3
  - gnai2b
  - gnai2a
  - smad2
  - yap1
  - plcb4
  - prkcaa
  - dct
  - smad9
  - oca2
  - efna2a
  - PLX4032
  - O-PLX4032
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Melanoma
  - Noonan syndrome
---
